SEARCH

SEARCH BY CITATION

(P = Proceedings, S = Supplement)

AFFOLTER, J.T., NEWBY, D.E., WILKINSON, I.B., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. No effect on central or peripheral blood pressure of systemic urotensin II infusion in man: 617

AFFRIME, M.B. see KOSOGLOU, T.

AGNEW, J.R. see COREY, A.E.

AKAGAWA, N. see FURUTA, S.

AL-RASHED, S.A., WRIGHT, D.J., ROEBUCK, N., SUNTER, W. & CHRYSTYN, H. The value of inpatient pharmaceutical counselling to elderly patients prior to discharge: 657

AL-SHURBAJI, A. & TOKICS, L. The pharmacokinetics of ketobemidone in critically ill patients: 583

ALLAIN, H. see GANDON J.M.

ANDERSEN, V., PEDERSEN, N., LARSEN, N.-E., SONNE, J. & LARSEN, S. Intestinal first pass metabolism of midazolam in liver cirrhosis – effect of grapefruit juice: 120

ANHØO/>J, J. see LIPWORTH, B.J.

ARLETT, P. see HENDERSON, L.

ARMAND, J.P. see VAN KESTEREN, C.

ASK, B. see NORDMARK, A.

AUNGST, B.J. see SAITOH, H.

AUTRET-LECA, E., GIRAUDEAU, B., PLOYET, M.J. & JONVILLE-BÉRA, A.-P. Amoxicillin/clavulanic acid is ineffective at preventing otitis media in children with presumed viral upper respiratory infection: a randomized, double-blind equivalence, placebo-controlled trial: 652

AVILA, J. see DEBESA, F.

AYNACIOGLU, A.S. see NACAK, M.

BÄCKMAN, L., KREIS, H., MORALES, J.M., WILCZEK, H., TAYLOR, R. & BURKE, J.T. Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients: 65

BABER, N. Nurse Prescribing, 2nd edition: 684

BACHETONI, A. see QUINTIERI, F.

BACK, D.J. see BOFFITO, M.

BAGHERI, H. see BONGARD, V.

BALMENT, R.J. see AFFOLTER, J.T.

BANNON, P. see ROY, L.

BARRETT, J. see SNELL, P.

BATEMAN, D.N. see SHEEN, C.L.

BATEMAN, D.N., GOOD, A.M., KELLY, C.A. & LAING, W.J. Web based information on clinical toxicology for the United Kingdom: uptake and utilization of TOXBASE in 2000: 3

BATRA, V.K. see KOSOGLOU, T.

BÉGAUD, B., BERGMAN, U., EICHLER, H.-G., LEUFKENS, H.G.M. & MEIER, P.J. Drug reimbursement: Indicators of inappropriate resource allocation: 528

BÉGAUD, B., MARTIN, K., FOURRIER, A. & HARAMBURU, F. Does age increase the risk of adverse drug reactions?: 550

BEGG, E.J. see WHITING, B.

BEIJNEN, J.H. see DE MAAT, M.M.R., VAN KESTEREN, C.

BERGMAN, U. see BÉGAUD, B., DE PONTI, F.

BERGQUIST, C. see HENDERSON, L.

BIANCHETTI, M.G. see VON VIGIER, R.O.

BISGAARD, H. see LIPWORTH, B.J.

BJERRUM, L. see DE PONTI, F.

BLACKMAN, D.J. see SCHMITT, M.

BLAIS, L. see DENDUKURI, N.

BOASE, S. & MINERS, J.O. In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine: 493

BOCHNER, F. Drug benefits and risks; International Textbook of Clinical Pharmacology: 186

BOFFITO, M., HOGGARD, P.G., REYNOLDS, H.E., BONORA, S., MEADEN, E.R., SINICCO, A., PERRI, G.D. & BACK, D.J. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects: 262

BONATO, P.S. see TAKAYANAGUI, O.M.

BONGARD, V., MÉNARD-TACHÉ, S., BAGHERI, H., KABIRI, K., LAPEYRE-MESTRE, M. & MONTASTRUC, J.L. Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals: 433

BONHAM, J.R. see MATTHEWS, A.

BONORA, S. see BOFFITO, M.

BRÄUTIGAM, L. see GRUNDMANN-KOLLMANN, M.

BRATER, D.C. Measurement of renal function during drug development: 87

BROCKMÖLLER, J. see MEINEKE, I.

BRUNNER, M., REINPRECHT, A., ILLIEVICH, U., SPISS, C.K., DITTRICH, P., VAN HOUTE, M. & MÜLLER, M. Penetration of fosfomycin into the parenchyma of human brain: a case study in three patients: 548

BURCH, R.M. see GALE, D.D.

BURGGRAAF, J. see FAAIJ, R.A., KEMME, M.J.B.

BURIAN, M., GRÖSCH, S., TEGEDER, I. & GEISSLINGER, G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population: 518

BURKE, J.T. see BÄCKMAN, L.

BUSS, N.E. see MOYLE, G.J.

BYE, A. see TENEGGI, V.

CARPENTER, P. see LEFÈVRE, G.

CASCORBI, I. see GERLOFF, T., NACAK, M.

CHAKRAPANI, A. see MATTHEWS, A.

CHAN, C. see WISE, S.D.

CHEE, Y.K. see UNGVARI, G.S.

CHEN, X.-P. see HAN, X.-M.

CHIRINO-BARCELO, Y. see LEE, H.S.

CHIU, H.F.K. see UNGVARI, G.S.

CHLÁDEK, J., GRIM, J., MARTÍNKOVÁ, J., SˇIMKOVÁ, M., VANÌÈKOVÁ, J., KOUDELKOVÁ, V. & NOIÈKOVÁ, M. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis: 147

CHRISTENSEN, M. see YASAR, Ü.

CHRYSTYN, H. see AL-RASHED, S.A., SILKSTONE, V.L.

CHUNG, Y.G. see UNGVARI, G.S.

COCKCROFT, J.R. see SCHMITT, M.

COHEN, A.F. see FAAIJ, R.A., KEMME, M.J.B.

COLLER, J.K., KREBSFAENGER, N., KLEIN, K., ENDRIZZI, K., WOLBOLD, R., LANG, T., NÜSSLER, A., NEUHAUS, P., ZANGER, U.M., EICHELBAUM, M. & MÜRDTER, T.E. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver: 157

COREY, A.E., AGNEW, J.R., VALENTINE, S.N., PAREKH, N.J., POWELL, J.H. & THOMPSON, G.A. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration: 449

CORLETT, S.A. see SILKSTONE, V.L.

CREMA, F. see DE PONTI, F.

CUTLER, D.L. see KOSOGLOU, T.

CUTTS, C., LACAZE, A. & TETT, S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice: 522

D’AMBROSIO, A. see QUINTIERI, F.

DAHL, M.-L. see YASAR, Ü.

DALY, A.K. see GILHOOLY, T.C.

DAMLE, B., ULLAH, I., DOLL, W., WILEY, G. & KNUPP, C. Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteers: 255

DANHOF, M. see KNIBBE, C.A.J.

DAVIES, D.S. see SHAUNAK, S.

DE BOER, A. see VAN DE VIJVER, D.A.M.C.

DE KONING, G.H.P. see DERIJKS, H.J.

DE MAAT, M.M.R., HUITEMA, A.D.R., MULDER, J.W., MEENHORST, P.L., VAN GORP, E.C.M. & BEIJNEN, J.H. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals: 378

DE PONTI, F. & CREMA, F. Serotonergic modulating drugs for functional GI disease: the complex pharmacology of serotonergic drugs: 680

DE PONTI, F., POLUZZI, E., VACCHERI, A., BERGMAN, U., BJERRUM, L., FERGUSON, J., FRENZ, K.J., MCMANUS, P., SCHUBERT, I., SELKE, G., TERZIS-VASLAMATZIS, G. & MONTANARO, N. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries: 171

DEARY, I. see WATSON, J.

DEBESA, F., JIMÉNEZ, G., FIGUERAS, A., DIOGÈNE, E., PEÑA, J.P., AVILA, J. & LAPORTE, J.-R. Spontaneous reporting of adverse drug reactions in Cuba: integrating continuous education, training and research in a network approach: 335

DENDUKURI, N., BLAIS, L. & LELORIER, J. Inhaled corticosteroids and the risk of diabetes among the elderly: 59

DERIJKS, H.J., DE KONING, G.H.P., MANTEL-TEEUWISSE, A.K. & EGBERTS, A.C.G. Limited adherence to safety instructions in drug leaflets: 678

DILLON, J.F. see SHEEN, C.L.

DIOGÈNE, E. see DEBESA, F.

DITTRICH, P. see BRUNNER, M.

DOKOUMETZIDIS, A., ILIADIS, A. & MACHERAS, P. Nonlinear dynamics in Clinical Pharmacology: the paradigm of cortisol secretion and suppression: 21

DOLL, W. see DAMLE, B.

DOORSTAM, D.P. see TIMMER, C.J.

DORR, A. see SNELL, P.

DOSTERT, P. see PECKING, M.

DREOSSI, S.A.C. see TAKAYANAGUI, O.M.

DRUMMOND, P.D. Prior iontophoresis of saline enhances vasoconstriction to phenylephrine and clonidine in the skin of the human forearm: 45

EDEFONTI, A. see VON VIGIER, R.O.

EGBERTS, A.C.G. see DERIJKS, H.J.

EICHELBAUM, M. see COLLER, J.K.

EICHLER, H.-G. see BÉGAUD, B.

EKINCI, E. see NACAK, M.

ELIASSON, E. see SANDBERG, M., YASAR, Ü.

ELLIOTT, P.J. see SHAH, I.M.

ENDRIZZI, K. see COLLER, J.K.

ERDAL, M.E. see NACAK, M.

ERNST, E. A systematic review of systematic reviews of homeopathy: 577

FAAIJ, R.A., BURGGRAAF, J., SCHOEMAKER, R.C., VAN AMSTERDAM, R.G.M. & COHEN, A.F. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin: 304

FAWCETT, J.P. see ZHANG, M.

FERGUSON, J. see DE PONTI, F.

FERRARI, M. see GUSELLA, M.

FERRAZZI, E. see GUSELLA, M.

FIGUERAS, A. see DEBESA, F.

FILIZ, A. see NACAK, M.

FORBES, S. see JOHNSTON, D.G.

FOSSALI, E. see VON VIGIER, R.O.

FOURRIER, A. see BÉGAUD, B.

FRANCES, C. see TRENQUE, T.

FRENNEAUX, M.P. see SCHMITT, M.

FRENZ, K.J. see DE PONTI, F.

FREUDENTHALER, S. see MEINEKE, I.

FUJIMURA, M. see MYOU, S.

FUJISAKI, H. see SAITOH, H.

FUJITA, T., MATSUMOTO, Y., KIMURA, T., YOKOTA, S., SAWADA, M., MAJIMA, M., OHTANI, Y. & KUMAGAI, Y. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5α-reductase inhibitor, in normal subjects treated with single or multiple doses: 283

FUMOLEAU, P. see VAN KESTEREN, C.

FUNG-SHING, N. see UNGVARI, G.S.

FURUTA, S., AKAGAWA, N., KAMADA, E., HIYAMA, A., KAWABATA, Y., KOWATA, N., INABA, A., MATTHEWS, A., HALL, M. & KURIMOTO, T. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential: 295

GALE, D.D., LANDELLS, L.J., SPINA, D., MILLER, A.J., SMITH, K., NICHOLS, T., ROTSHTEYN, Y., TONELLI, A., LACOUTURE, P., BURCH, R.M., PAGE, C.P. & O’CONNOR, B.J. Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers: 478

GANDON, J.M. & ALLAIN, H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers: 51

GEISSLINGER, G. see BURIAN, M., GRUNDMANN-KOLLMANN, M.

GERDEN, B. see HENDERSON, L.

GERLOFF, T., SCHAEFER, M., JOHNE, A., OSELIN, K., MEISEL, C., CASCORBI, I. & ROOTS I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males: 610

GERMAIN, M.L. see TRENQUE, T.

GILHOOLY, T.C. & DALY, A.K. CYP2D6 deficiency, a factor in ecstasy related deaths?: 69

GIRAUDEAU, B. see AUTRET-LECA, E.

GLEITER, C.H. see MEINEKE, I.

GOGGIN, T. see MOYLE, G.J.

GOLDBERG, M.R. see STRACHAN, F.E.

GOMENI, R. see TENEGGI, V.

GOOD, A.M. see BATEMAN, D.N.

GRØNVALL, J. see HUTCHINGS, M.

GRANATH, F. see NORDMARK, A.

GRIM, J. see CHLÁDEK, J.

GRÖSCH, S. see BURIAN, M.

GRUNDMANN-KOLLMANN, M., PODDA, M., BRÄUTIGAM, L., HARDT-WEINELT, K., LUDWIG, R.J., GEISSLINGER, G., KAUFMANN, R. & TEGEDER, I. Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration: 535

GUSELLA, M., TOSO, S., FERRAZZI, E., FERRARI, M. & PADRINI, R. Relationships between body composition parameters and fluorouracil pharmacokinetics: 131

HABIBA, N.M. see RAO, P.K.

HAGIWARA, N. see OMORI, H.

HALL, M. see FURUTA, S.

HAN, X.-M., OUYANG, D.-S., CHEN, X.-P., SHU, Y., JIANG, C.-H., TAN, Z.-R. & ZHOU, H.-H. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2: 540

HARAMBURU, F. see BÉGAUD, B.

HARDT-WEINELT, K. see GRUNDMANN-KOLLMANN, M.

HASHIMOTO, T. see MYOU, S.

HATAKEYAMA, Y. see SAITOH, H.

HAWKINS, D.A. see MOYLE, G.J.

HE, M.M. see WISE, S.D.

HEIKKINEN, H., VARHE, A., LAINE, T., PUTTONEN, J., KELA, M., KAAKKOLA, S. & REINIKAINEN, K. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose: 363

HENDERSON, L., YUE, Q.Y., BERGQUIST, C., GERDEN, B. & ARLETT, P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes: 349

HESSE, B. see HUTCHINGS, M.

HIGGS, C. see MOYLE, G.J.

HIYAMA, A. see FURUTA, S.

HÖÖG, J.-O. see SANDBERG, M.

HOFMANN, U. see MEINEKE, I.

HOGGARD, P.G. see BOFFITO, M.

HOIZEY, G. see TRENQUE, T.

HOLFORD, N.H.G. see WHITING, B.

HOMERY, M.-C. see PECKING, M.

HOREN, B., MONTASTRUC, J.-L. & LAPEYRE-MESTRE, M. Adverse drug reactions and off-label drug use in paediatric outpatients: 665

HUITEMA, A.D.R. see DE MAAT, M.M.R.

HUTCHINGS, M., HESSE, B., GRØNVALL, J. & OLSEN, N.V. Renal 131I-hippuran extraction in man: effects of dopamine: 675

IAVARONE, L. see TENEGGI, V.

IKEDA, Y., UMEMURA, K., KONDO, K., NAKASHIMA, M., KOBAYASHI, T. & TAKAHASHI, M. Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers: 453

ILIADIS, A. see DOKOUMETZIDIS, A.

ILLIEVICH, U. see BRUNNER, M.

INABA, A. see FURUTA, S.

ISHIURA, Y. see MYOU, S.

ISHIZUKA, N. see OMORI, H.

JANSEN, P.A.F. see VAN DE VIJVER, D.A.M.C.

JIANG, C.-H. see HAN, X.-M.

JICK, H. see SCHLIENGER, R.G.

JIMÉNEZ, G. see DEBESA, F.

JOHNE, A. see GERLOFF, T.

JOHNSON, T.N. Complementary therapies for pharmacists: 187

JOHNSON, T.N. see MATTHEWS, A.

JOHNSTON, D.G., ROBINSON, S. & FORBES, S. What should we measure in the diabetic patient and how does this respond to therapy?: 81

JONES, A.W. see KLOCKHOFF, H.

JONVILLE-BÉRA, A.-P. see AUTRET-LECA, E.

JORASCHKY, P. see SIEPMANN, M.

KAAKKOLA, S. see HEIKKINEN, H.

KABIRI, K. see BONGARD, V.

KAMADA, E. see FURUTA, S.

KAMIO, Y. see MYOU, S.

KASANUKI, H. see OMORI, H.

KAUFMANN, R. see GRUNDMANN-KOLLMANN, M.

KAWABATA, Y. see FURUTA, S.

KAWANA, M. see OMORI, H.

KELA, M. see HEIKKINEN, H.

KELLAND, N.F. & WEBB, D.J. ACE inhibitors: 337

KELLOGG, D.L. see RAO, P.K.

KELLY, C.A. see BATEMAN, D.N.

KEMME, M.J.B., BURGGRAAF, J., SCHOEMAKER, R.C., KLUFT, C. & COHEN, A.F. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose: 627

KERR, D. see WATSON, J.

KERWIN, R.W. see SHAIKH, S.

KHOO, Y.M. see LEE, H.S.

KIMURA, T. see FUJITA, T.

KIRBY, B. The Desktop Guide to Complementary and Alternative Medicine: 71

KIRCH, W. see SIEPMANN, M.

KITA, T. see MYOU, S.

KLEIN, K. see COLLER, J.K.

KLOCKHOFF, H., NÄSLUND, I. & JONES, A.W. Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery: 587

KLUFT, C. see KEMME, M.J.B.

KNIBBE, C.A.J., MELENHORST-DE JONG, G., MESTROM, M., RADEMAKER, C.M.A., REIJNVAAN, A.F.A., ZUIDEVELD, K.P., KUKS, P.F.M., VAN VUGHT, H. & DANHOF, M. Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery: 415

KNUPP, C. see DAMLE, B.

KOBAYASHI, M. see SAITOH, H.

KOBAYASHI, T. see IKEDA, Y.

KOKWARO, G.O. see OGUTU, B.R.

KONDO, K. see IKEDA, Y.

KOSOGLOU, T., MEYER, I., VELTRI, E.P., STATKEVICH, P., YANG, B., ZHU, Y., MELLARS, L., MAXWELL, S.E., PATRICK, J.E., CUTLER, D.L., BATRA, V.K. & AFFRIME, M.B. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin: 309

KOUDELKOVÁ, V. see CHLÁDEK, J.

KOWATA, N. see FURUTA, S.

KRAUSE, S. see SIEPMANN, M.

KREBSFAENGER, N. see COLLER, J.K.

KREIS, H. see BÄCKMAN, L.

KUKS, P.F.M. see KNIBBE, C.A.J.

KUMAGAI, Y. see FUJITA, T.

KURIMOTO, T. see FURUTA, S.

KWON, J.-T. see YOSHIDA, R.

KWONG, T.W. see UNGVARI, G.S.

LACAZE, A. see CUTTS, C.

LACOUTURE, P. see GALE, D.D.

LAINE, T. see HEIKKINEN, H.

LAING, W.J. see BATEMAN, D.N.

LANCHOTE, V.L. see TAKAYANAGUI, O.M.

LANDELLS, L.J. see GALE, D.D.

LANG, T. see COLLER, J.K.

LANGMAN, M.J.S. see LEWIS, S.C.

LAPEYRE-MESTRE, M. see BONGARD, V., HOREN, B.

LAPORTE, J.-R. see DEBESA, F.. LEWIS, S.C.

LARSEN, N.-E. see ANDERSEN, V.

LARSEN, S. see ANDERSEN, V.

LEBLANC, M. see ROY, L.

LEE, D.K.C. see LIPWORTH, B.J.

LEE, H.S., KHOO, Y.M., CHIRINO-BARCELO, Y., TAN K.L. & ONG, D. Caffeine in apnoeic Asian neonates: a sparse data analysis: 31

LEES, K.R. see SHAH, I.M.

LEFÈVRE, G., CARPENTER, P., SOUPPART, C., SCHMIDLI, H. MCCLEAN, M. & STYPINSKI, D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjects: 485

LELORIER, J. see DENDUKURI, N.

LEUFKENS, H.G.M. see BÉGAUD, B.

LEWIS, S.C., LANGMAN, M.J.S., LAPORTE, J.-R., MATTHEWS, J.N.S., RAWLINS, M.D. & WIHOLM, B.-E. Dose–response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data: 320

LINDPAINTNER, K. Pharmacogenetics and the future of medical practice: 221

LINES, C. see TFELT-HANSEN, P.

LIPWORTH, B.J. Antagonism of long-acting β2-adrenoceptor agonism: 231

LIPWORTH, B.J., LEE, D.K.C., ANHØJ, J. & BISGAARD, H. Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children: 544

LIU, Y. see RAO, P.K.

LOWE, G.D.O. Measurement of thrombosis and its prevention: 96

LUDWIG, R.J. see GRUNDMANN-KOLLMANN, M.

LUNDGREN, S. see NORDMARK, A.

MACDONALD, T.M. see SHEEN, C.L.

MACHERAS, P. see DOKOUMETZIDIS, A.

MAJIMA, M. see FUJITA, T.

MALIK, M. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval: 682

MANTEL-TEEUWISSE, A.K. see DERIJKS, H.J.

MARQUET, P. see PECKING, M.

MARTÍNKOVÁ, J. see CHLÁDEK, J.

MARTIN, K. see BÉGAUD, B.

MARTIN, P.D., MITCHELL, P.D. & SCHNECK, D.W. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers: 472

MATHÔT, R.A.A. see VAN KESTEREN, C.

MATSUMOTO, Y. see FUJITA, T.

MATTHEWS, A. see FURUTA, S.

MATTHEWS, A., JOHNSON, T.N., ROSTAMI-HODJEGAN, A., CHAKRAPANI, A., WRAITH, J.E., MOAT, S.J., BONHAM, J.R. & TUCKER, G.T. An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria: 140

MATTHEWS, J.N.S. see LEWIS, S.C.

MAXWELL, S.E. see KOSOGLOU, T.

MAXWELL, S.R.J. see WEBB, D.J.

MCCLEAN, M. see LEFÈVRE, G.

MCCREA, J.B. see STRACHAN, F.E.

MCMANUS, P. see DE PONTI, F.

MÉNARD-TACHÉ, S. see BONGARD, V.

MEADEN, E.R. see BOFFITO, M.

MEENHORST, P.L. see DE MAAT, M.M.R.

MEIER, C.R. see SCHLIENGER, R.G.

MEIER, P.J. see BÉGAUD, B.

MEINEKE, I., FREUDENTHALER, S., HOFMANN, U., SCHAEFFELER, E., MIKUS, G., SCHWAB, M., PRANGE, H.W., GLEITER, C.H. & BROCKMÖLLER, J. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine: 592

MEISEL, C. see GERLOFF, T.

MELENHORST-DE JONG, G. see KNIBBE, C.A.J.

MELLARS, L. see KOSOGLOU, T.

MESTROM, M. see KNIBBE, C.A.J.

MEYER, I. see KOSOGLOU, T.

MIDDLETON, G.W. see SCHMITT, M.

MIKUS, G. see MEINEKE, I.

MILLART, H. see TRENQUE, T.

MILLER, A.J. see GALE, D.D.

MILLERI, S. see TENEGGI, V.

MINERS, J.O. see BOASE, S.

MITCHELL M.I. see WISE, S.D.

MITCHELL, P.D. see MARTIN, P.D.

MIYAZAKI, K. see SAITOH, H.

MOAT, S.J. see MATTHEWS, A.

MONTANARO, N. see DE PONTI, F.

MONTASTRUC, J.-L. see HOREN, B.

MONTASTRUC, J.L. see BONGARD, V.

MONTESTRUC, F. see PECKING, M.

MORALES, J.M. see BÄCKMAN, L.

MORRIS, R.G. see SALLUSTIO, B.C.

MOYLE, G.J., BUSS, N.E., GOGGIN, T., SNELL, P., HIGGS, C. & HAWKINS, D.A. Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV: 178

MÜCK-WEYMANN, M. see SIEPMANN, M.

MÜLLER, M. see BRUNNER, M.

MÜRDTER, T.E. see COLLER, J.K.

MUCHOHI, S.N. see OGUTU, B.R.

MULDER, J.W. see DE MAAT, M.M.R.

MURRAY, S. Introduction to proteomics: 338

MYOU, S., FUJIMURA, M., KAMIO, Y., KITA, T., WATANABE, K., ISHIURA, Y., HASHIMOTO, T. & NAKAO, S. Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma: 622

NÄSLUND, I. see KLOCKHOFF, H.

NACAK, M., AYNACIOGLU, A.S., FILIZ, A., CASCORBI, I., ERDAL, M.E., YILMAZ, N., EKINCI, E. & ROOTS, I. Association between the N-acetylation genetic polymorphism and bronchial asthma: 671

NAGASHIMA, H. see OMORI, H.

NAKAJIMA, M. see YOSHIDA, R.

NAKAO, S. see MYOU, S.

NAKASHIMA, M. see IKEDA, Y.

NEUHAUS, P. see COLLER, J.K.

NEWBY, D.E. see AFFOLTER, J.T., STRACHAN, F.E.

NEWTON, C.R.J.C. see OGUTU, B.R.

NICHOLS, T. see GALE, D.D.

NIMMO, W.S. & TUCKER, G. 3rd meeting on clinical measurement and new drug development, Royal Society of Edinburgh, 13–14 June 2001: 73P

NOIÈKOVÁ, M. see CHLÁDEK, J.

NORDMARK, A., LUNDGREN, S., ASK, B., GRANATH, F. & RANE, A. The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women: 504

NÜSSLER, A. see COLLER, J.K.

O’CONNOR, B.J. see GALE, D.D.

OGUTU, B.R., NEWTON, C.R.J.C., MUCHOHI, S.N., OTIENO, G.O. & KOKWARO, G.O. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration: 635

OHTANI, Y. see FUJITA, T.

OHWADA, K. see SAITOH, H.

OLSEN, N.V. see HUTCHINGS, M.

OMORI, H., NAGASHIMA, H., TSURUMI, Y., TAKAGI, A., ISHIZUKA, N., HAGIWARA, N., KAWANA, M. & KASANUKI, H. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects: 395

ONG, D. see LEE, H.S.

OO, C. see SNELL, P.

OSELIN, K. see GERLOFF, T.

OTIENO, G.O. see OGUTU, B.R.

OUYANG, D.-S. see HAN, X.-M.

PADRINI, R. see GUSELLA, M.

PAGE, C.P. see GALE, D.D.

PAINE, M.F. see WANWIMOLRUK, S.

PAREKH, N.J. see COREY, A.E.

PATRICK, J.E. see KOSOGLOU, T.

PÉRGOLA, P.E. see RAO, P.K.

PECKING, M., MONTESTRUC, F., MARQUET, P., WODEY, E., HOMERY, M.-C. & DOSTERT, P. Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers: 357

PEDERSEN, N. see ANDERSEN, V.

PEÑA, J.P. see DEBESA, F.

PERRI, G.D. see BOFFITO, M.

PIEN, C.P. see SHAH, I.M.

PLOYET, M.J. see AUTRET-LECA, E.

PODDA, M. see GRUNDMANN-KOLLMANN, M.

POLUZZI, E. see DE PONTI, F.

PORSIUS, A.J. see VAN DE VIJVER, D.A.M.C.

POULIQUEN I.J. see WISE, S.D.

POWELL, J.H. see COREY, A.E.

PRANGE, H.W. see MEINEKE, I.

Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 19 April 2002: 553P

PUNT, C. see VAN KESTEREN, C.

PUSEK, S.N. see WANWIMOLRUK, S.

PUTTONEN, J. see HEIKKINEN, H.

QUINTIERI, F., D’AMBROSIO, A. & BACHETONI, A. The effect of diltiazem, a calcium channel blocker, in asthmatic patients: 679

RADEMAKER, C.M.A. see KNIBBE, C.A.J.

RANE, A. see NORDMARK, A.

RAO, P.K., PÉRGOLA, P.E., HABIBA, N.M., LIU, Y. & KELLOGG, D.L. Double injection vs skin microdialysis technique in minimally invasive in vivo pharmacology: 333

RAVIC, M. see VAN KESTEREN, C.

RAWLINS, M.D. see LEWIS, S.C.

RAYMOND, E. see VAN KESTEREN, C.

REIJNVAAN, A.F.A. see KNIBBE, C.A.J.

REINIKAINEN, K. see HEIKKINEN, H.

REINPRECHT, A. see BRUNNER, M.

REYNOLDS, H.E. see BOFFITO, M.

ROBINSON, S. see JOHNSTON, D.G.

ROEBUCK, N. see AL-RASHED, S.A.

ROOS, R.A.C. see VAN DE VIJVER, D.A.M.C.

ROOTS, I. see GERLOFF, T., NACAK, M.

ROSTAMI-HODJEGAN, A. see MATTHEWS, A.

ROTSHTEYN, Y. see GALE, D.D.

ROY, L., LEBLANC, M., BANNON, P. & VILLENEUVE, J.-P. Quinine pharmacokinetics in chronic haemodialysis patients: 604

SˇIMKOVÁ, M. see CHLÁDEK, J.

SAITOH, H., AUNGST, B.J., TOHYAMA, M., HATAKEYAMA, Y., OHWADA, K., KOBAYASHI, M., FUJISAKI, H. & MIYAZAKI, K. In vitro permeation of β-lactam antibiotics across rat jejunum and its correlation with oral bioavailability in humans: 445

SALLUSTIO, B.C., WESTLEY, I.S. & MORRIS, R.G. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose: 107

SANDBERG, M., YASAR, Ü., STRÖMBERG, P., HÖÖG, J.-O. & ELIASSON, E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase: 423

SAWADA, M. see FUJITA, T.

SCHAEFER, H.G. see WISE, S.D.

SCHAEFER, M. see GERLOFF, T.

SCHAEFFELER, E. see MEINEKE, I.

SCHELLENS, J.H.M. see VAN KESTEREN, C.

SCHLIENGER, R.G., JICK, H. & MEIER, C.R. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction: 327

SCHMIDLI, H. see LEFÈVRE, G.

SCHMITT, M., BLACKMAN, D.J., MIDDLETON, G.W., COCKCROFT, J.R. & FRENNEAUX, M.P. Assessment of venous capacitance. Radionuclide plethysmography: methodology and research applications: 565

SCHNECK, D.W. see MARTIN, P.D.

SCHOEMAKER, R.C. see FAAIJ, R.A., KEMME, M.J.B.

SCHUBERT, I. see DE PONTI, F.

SCHWAB, M. see MEINEKE, I.

SCIBERRAS, D.G. see STRACHAN, F.E.

SEIDELIN, K. see TFELT-HANSEN, P.

SELKE, G. see DE PONTI, F.

SHAH, I.M., LEES, K.R., PIEN, C.P. & ELLIOTT, P.J. Early clinical experience with the novel proteasome inhibitor PS–519: 269

SHAH, R.R. The significance of QT interval in drug development: 188

SHAIKH, S. & KERWIN, R.W. Receptor pharmacogenetics: relevance to CNS syndromes: 344

SHAUNAK, S. & DAVIES, D.S. Surrogacy in antiviral drug development: 75

SHAW, J.P. see ZHANG, M.

SHEEN, C.L., DILLON, J.F., BATEMAN, D.N., SIMPSON, K.J. & MACDONALD, T.M. Paracetamol-related deaths in Scotland, 1994 –2000: 430

SHEINER, L.B. Is intent-to-treat analysis always (ever) enough?: 203

SHU, Y. see HAN, X.-M.

SIEPMANN, M., KRAUSE, S., JORASCHKY, P., MÜCK-WEYMANN, M. & KIRCH, W. The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men: 277

SILKSTONE, V.L., CORLETT, S.A. & CHRYSTYN, H. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization: 115

SIMPSON, K.J. see SHEEN, C.L.

SINICCO, A. see BOFFITO, M.

SMITH, K. see GALE, D.D.

SNELL, P. see MOYLE, G.J.

SNELL, P., OO, C., DORR, A. & BARRETT, J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids: 372

SONNE, J. see ANDERSEN, V.

SOUPPART, C. see LEFÈVRE, G.

SPILLER, R. Treatment of functional gastrointestinal diseases: 11

SPILLER, R. Treatment of functional GI disease: the complex pharmacology of serotonergic drugs. Reply from author: 681

SPINA, D. see GALE, D.D.

SPISS, C.K. see BRUNNER, M.

SQUASSANTE, L. see TENEGGI, V.

STATKEVICH, P. see KOSOGLOU, T.

STEPANAVAGE, M. see TFELT-HANSEN, P.

STRACHAN, F.E., NEWBY, D.E., SCIBERRAS, D.G., MCCREA, J.B., GOLDBERG, M.R. & WEBB, D.J. Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography: 386

STRÖMBERG, P. see SANDBERG, M.

STYPINSKI, D. see LEFÈVRE, G.

SUNTER, W. see AL-RASHED, S.A.

TAKAGI, A. see OMORI, H.

TAKAHASHI, M. see IKEDA, Y.

TAKAYANAGUI, O.M., BONATO, P.S., DREOSSI, S.A.C. & LANCHOTE, V.L. Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis: 125

TAN K.L. see LEE, H.S.

TAN, Z.-R. see HAN, X.-M.

TAYLOR, R. see BÄCKMAN, L.

TEGEDER, I. see BURIAN, M.

TEGEDER, I. see GRUNDMANN-KOLLMANN, M.

TENEGGI, V., SQUASSANTE, L., IAVARONE, L., MILLERI, S., BYE, A. & GOMENI, R. Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving: 407

TERZIS-VASLAMATZIS, G. see DE PONTI, F.

TETT, S. see CUTTS, C.

TFELT-HANSEN, P., SEIDELIN, K., STEPANAVAGE, M. & LINES, C. The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects: 38

THOMPSON, G.A. see COREY, A.E.

TIMMER, C.J., VERHEUL H.A.M. & DOORSTAM, D.P. Pharmacokinetics of tibolone in early and late postmenopausal women: 101

TOHYAMA, M. see SAITOH, H.

TOKICS, L. see AL-SHURBAJI, A.

TONELLI, A. see GALE, D.D.

TOSO, S. see GUSELLA, M.

TRENQUE, T., FRANCES, C., MILLART, H., HOIZEY, G. & GERMAIN, M.L. Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000: 548

TSURUMI, Y. see OMORI, H.

TUCKER, G. see NIMMO, W.S.

TUCKER, G.T. see MATTHEWS, A.

ULLAH, I. see DAMLE, B.

UMEMURA, K. see IKEDA, Y.

UNGVARI, G.S., CHUNG, Y.G., CHEE, Y.K., FUNG-SHING, N., KWONG, T.W. & CHIU, H.F.K. The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999: 437

URQUHART, J. The odds of the three nons when an aptly prescribed medicine isn’t working non-compliance, non-absorption, non-response: 212

VACCHERI, A. see DE PONTI, F.

VALENTINE, S.N. see COREY, A.E.

VAN AMSTERDAM, R.G.M. see FAAIJ, R.A.

VAN DE VIJVER, D.A.M.C., ROOS, R.A.C., JANSEN, P.A.F., PORSIUS, A.J. & DE BOER, A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa: 168

VAN GORP, E.C.M. see DE MAAT, M.M.R.

VAN HOUTE, M. see BRUNNER, M.

VAN KESTEREN, C., MATHÔT, R.A.A., RAYMOND, E., ARMAND, J.P., FUMOLEAU, P., PUNT, C., RAVIC, M., WANDERS, J., BEIJNEN, J.H. & SCHELLENS, J.H.M. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide): 463

VAN VUGHT, H. see KNIBBE, C.A.J.

VANÌÈKOVÁ, J. see CHLÁDEK, J.

VARHE, A. see HEIKKINEN, H.

VELTRI, E.P. see KOSOGLOU, T.

VERHEUL H.A.M. see TIMMER, C.J.

VILLENEUVE, J.-P. see ROY, L.

VOGT, B. see VON VIGIER, R.O.

VON VIGIER, R.O., FOSSALI, E., EDEFONTI, A., VOGT, B. & BIANCHETTI, M.G. Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers: 334

WANDERS, J. see VAN KESTEREN, C.

WANWIMOLRUK, S., PAINE, M.F., PUSEK, S.N. & WATKINS, P.B. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?: 643

WATANABE, K. see MYOU, S.

WATANABE, Y. see YOSHIDA, R.

WATKINS, P.B. see WANWIMOLRUK, S.

WATSON, J., DEARY, I. & KERR, D. Central and peripheral effects of sustained caffeine use: tolerance is incomplete: 400

WEBB, D.J. & MAXWELL, S.R.J. A spoonful of sugar? Tomorrow's Doctors 2002: 341

WEBB, D.J. see AFFOLTER, J.T., KELLAND, N.F., STRACHAN, F.E.

WESTLEY, I.S. see SALLUSTIO, B.C.

WHITING, B., HOLFORD, N.H.G. & BEGG, E.J. Clinical Pharmacology: Principles and practice of drug therapy in medical education: 1

WIHOLM, B.-E. see LEWIS, S.C.

WILCZEK, H. see BÄCKMAN, L.

WILEY, G. see DAMLE, B.

WILKINSON, I.B. see AFFOLTER, J.T.

WINTER, M.J. see AFFOLTER, J.T.

WISE, S.D., CHAN, C., SCHAEFER, H.G., HE, M.M., POULIQUEN, I.J. & MITCHELL, M.I. Quinidine does not affect the renal clearance of moxonidine: 251

WODEY, E. see PECKING, M.

WOLBOLD, R. see COLLER, J.K.

WRAITH, J.E. see MATTHEWS, A.

WRIGHT, D.J. see AL-RASHED, S.A.

YANG, B. see KOSOGLOU, T.

YASAR, Ü. see SANDBERG, M.

YASAR, Ü., DAHL, M.-L., CHRISTENSEN, M. & ELIASSON, E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity: 183

YILMAZ, N. see NACAK, M.

YOKOI, T. see YOSHIDA, R.

YOKOTA, S. see FUJITA, T.

YOSHIDA, R., NAKAJIMA, M., WATANABE, Y., KWON, J.-T. & YOKOI, T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism: 511

YUE, Q.Y. see HENDERSON, L.

ZANGER, U.M. see COLLER, J.K.

ZHANG, M., FAWCETT, J.P. & SHAW, J.P. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human: 246

ZHOU, H.-H. see HAN, X.-M.

ZHU, Y. see KOSOGLOU, T.

ZUIDEVELD, K.P. see KNIBBE, C.A.J.